Swiss startup Oculis secures €13.8M funding to treat ophthalmic diseases
Lausanne-based clinical-stage biopharmaceutical startup Oculis has secured €13.8 million in Series B annexe funding round by led Tekla Capital Management, with participation from Nan Fung Life Sciences and existing investors.